🍪 Our Cookies

This website uses cookies, pixel tags, and similar technologies (“Cookies”) for the purpose of enabling site operations and for performance, personalisation, and marketing purposes. We use our own Cookies and some from third parties. Only essential Cookies are used by default. By clicking “Accept All” you consent to the use of non-essential Cookies (i.e., functional, analytics, and marketing Cookies) and the related processing of personal data. You can manage your consent preferences by clicking Manage Preferences. You may withdraw a consent at any time by using the link “Cookie Preferences” in the footer of our website.

Our Privacy Notice is accessible here. To learn more about the use of Cookies on our website, please view our Cookie Notice.

Arxada’s tough path to deleveraging — Analysis

Share

News and Analysis

Arxada’s tough path to deleveraging — Analysis

Varun Gianchandani's avatar
  1. Varun Gianchandani
•18 min read

Arxada's net leverage has risen from 6x in December 2021 to 9.1x in March 2024, driven by the weakness in the European chemicals industry.

The company's financing documents allow pro forma EBITDA add-backs (primarily cost-savings and synergies) for up to 24 months only, and are set to discontinue from December 2024. After this date, add-backs will need to translate into actual cash flow through higher EBITDA generation; otherwise, leverage will keep climbing.

Recently Published

What are you waiting for?

Try it out

  • We're trusted by 9 of the top 10 Investment Banks